Timothy Maher follows the lifespan of a new chemical entity from initial discovery, through synthesis, preclinical and clinical testing, to approval, launch and post-marketing surveillance. Maher charts the ups and downs along the way from before a drug is approved, through marketing, and use and beyond; and he answers questions like: What is a “black-box” warning? Who’s looking out for your well-being? Should “Fen-Phen” have ever happened? What about Vioxx? This project is supported by a Science Education Partnership Award (SEPA) from the National Center for Research Resources, National Institutes of Health. It does not necessarily represent the official views of NCRR or NIH.